Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
601-620 of 1,694 trials

Isatuximab for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

We are studying whether Isatuximab can safely help adults with relapsed or refractory T-cell acute lymphoblastic leukemia achieve remission. This trial looks at its effects alone and with other chemotherapy drugs.

T-cell Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Methylphenidate for Cancer-Related Fatigue in Young Brain Tumor Survivors

We are studying whether methylphenidate can help reduce fatigue in patients who were treated for brain tumors during childhood or adolescence. Additionally, we will look at its effects on sleep, cognitive function, and quality of life.

Cancer-related Fatigue after Pediatric Brain Tumor Treatment3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementOncologyPediatrics

Quizartinib for Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

We are studying whether quizartinib, combined with chemotherapy, can improve survival in adults with newly diagnosed FLT3-ITD negative AML compared to a placebo. This trial aims to assess its effectiveness and safety.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementOncology

Colchicine for Angina in Microvascular Disease

We are studying whether colchicine can improve blood flow and reduce symptoms in patients with angina caused by coronary microvascular dysfunction. This research may help us understand how to better treat this condition.

Cardiovascular Disease (CMD)>2 yearsEfficacy phase (II)Standard MedicinesCardiology

DZR123 for Advanced Solid Tumors and Lymphomas

We are studying a new treatment called DZR123 for patients with advanced solid tumors and lymphomas. The trial will help us understand its safety and how well it works alone and with another medication.

Advanced Solid Tumors and Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Lymphocytic Leukemia: Lisaftoclax Treatment Study

We are studying whether a new drug, lisaftoclax, combined with another treatment, helps patients with chronic lymphocytic leukemia who have been previously treated. The goal is to see if this combination improves survival and slows disease progression.

Chronic Lymphocytic Leukemia (CLL) / Small Cell Lymphocytic Lymphoma (SLL)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Endometrial Cancer: New Treatment Combinations

We are studying whether a new combination of Trastuzumab Deruxtecan with Rilvegostomig or Pembrolizumab is more effective than standard chemotherapy for patients with advanced or recurrent HER2-expressing endometrial cancer.

Endometrial CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Biliary Tract Cancer: T-DXd and Rilvegostomig Study

We are studying a new treatment combination for patients with advanced HER2-expressing biliary tract cancer. The goal is to see if it helps improve survival compared to standard care options.

Advanced HER2-expressing Biliary Tract Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Castrate-Resistant Prostate Cancer: Acetylsalicylic Acid and Atorvastatin Study

We are investigating whether acetylsalicylic acid and atorvastatin can improve survival in patients with castrate-resistant prostate cancer. The study will also look at other health impacts and safety of these medications.

Castration-Resistant Prostate CancerConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyUrology

Advanced Colon Cancer: Preoperative Chemotherapy Study

We are investigating whether chemotherapy before surgery is more effective than surgery followed by additional treatment for advanced colon cancer. This trial aims to improve treatment strategies for patients.

Colon Cancer (Stage T3-4)>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Postmenopausal Bone Health: Everolimus and Exercise Study

We are investigating whether everolimus, exercise, or both can improve bone formation in healthy postmenopausal women. This study aims to help prevent bone loss and support skeletal health.

Healthy Participants3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyInternal MedicineOrthopedics and Traumatology

Breast Cancer Treatment for Women 70+: Radiation vs. Hormone Therapy

We are comparing radiation therapy and hormone therapy for older women with early-stage luminal A-like breast cancer. The goal is to see which treatment better controls cancer and improves quality of life.

Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Childhood Absence Epilepsy: Brivaracetam Safety Study

We are studying the long-term safety of brivaracetam in children and young adults with childhood or juvenile absence epilepsy. This research aims to understand how well the medication is tolerated over time.

Childhood Absence EpilepsyJuvenile Absence Epilepsy>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Advanced Biliary Cancer: Personalized Targeted Therapy

We are studying whether a new personalized treatment can help patients with advanced biliary cancer live longer without disease progression compared to standard care. This trial also examines the quality of life and safety of the new therapies.

Advanced Biliary Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Lymphoblastic Lymphoma: New Treatment Protocol for Kids

We are studying whether changing medications during treatment can help reduce relapses in the brain for children and adolescents with lymphoblastic lymphoma. This trial aims to improve survival rates and treatment outcomes compared to standard approaches.

Lymphoblastic Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ROS1-Positive Lung Cancer: REPotrectinib Study

We are testing a new treatment for patients with ROS1-positive non-small cell lung cancer and active brain metastasis. The study aims to see how well it works in shrinking brain tumors and to assess its safety.

ROS1-positive Non-Small Cell Lung Cancer with Brain Metastasis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurologyOncology

Chronic Myeloid Leukemia: Asciminib for Kids

We are studying the safety and appropriate dose of asciminib in children with chronic myeloid leukemia. This research aims to ensure the medication is safe and effective for young patients who have already tried other treatments.

Philadelphia Positive Chronic Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

INBRX-109 for Advanced Solid Tumors, Including Sarcomas

We are studying a new treatment, INBRX-109, in combination with chemotherapy for adults and adolescents with advanced solid tumors like Ewing sarcoma and colorectal cancer. The goal is to assess its safety and how well it works compared to current treatments.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Thrombosis Prevention in Surgery: Apixaban Study

We are studying whether the medication apixaban can help prevent blood clots in patients undergoing general abdominal, gynecologic, and urologic surgeries. This trial compares its effects to not using any anticoagulants during surgery.

Venous Thromboembolism>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteGynecology and ObstetricsInternal MedicineOrthopedics and TraumatologyUrology

Heart Procedure: Short vs. Long Antiplatelet Therapy

We are studying whether a shorter duration of antiplatelet therapy after a heart procedure is as safe and effective as the standard longer treatment. This trial is for patients who have had coronary angioplasty for blocked arteries.

Chronically Occluded Coronary Artery>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine